Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals Limited has announced the release of 9,684 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Dedicaid GmbH. This release, scheduled for April 16, 2025, is in accordance with ASX Listing Rule 3.10A and reflects Telix’s ongoing strategic efforts to integrate acquisitions and enhance its market presence.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company focuses on addressing significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products.
YTD Price Performance: 15.37%
Average Trading Volume: 5,321
Technical Sentiment Signal: Sell
Current Market Cap: $5.63B
See more data about TLX stock on TipRanks’ Stock Analysis page.